Search Results

Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis.

• Authors : Krieter DH; Division of Nephrology, Department of Medicine, University Hospital Würzburg, Würzburg, Germany.; Devine E

Subjects: Acute Kidney Injury/Acute Kidney Injury/Acute Kidney Injury/*therapy ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacokinetics ; Boronic Acids/Boronic Acids/Boronic Acids/*pharmacokinetics

• Source: Artificial organs [Artif Organs] 2014 Oct; Vol. 38 (10), pp. 888-93. Date of Electronic Publication: 2014 Jan 07.Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7802778 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Periorbital necrobiotic xanthogranuloma treated successfully with novel multiple myeloma therapy.

• Authors : Ghani S; Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.; Al Ustwani O

Subjects: Multiple Myeloma* ; Necrobiotic Xanthogranuloma*/Necrobiotic Xanthogranuloma*/Necrobiotic Xanthogranuloma*/drug therapy ; Necrobiotic Xanthogranuloma*/Necrobiotic Xanthogranuloma*/Necrobiotic Xanthogranuloma*/pathology

• Source: Clinical advances in hematology & oncology : H&O [Clin Adv Hematol Oncol] 2013 Oct; Vol. 11 (10), pp. 678-80.Publisher: Millennium Medical Pub Country of Publication: United States NLM ID: 101167661 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.

• Authors : Richardson PG; Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. ; Laubach JP

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*adverse effects ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*adverse effects ; Asthenia/Asthenia/Asthenia/*chemically induced

• Source: Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2010 Feb; Vol. 8 Suppl 1, pp. S4-S12.Publisher: Harborside Press Country of Publication: United States NLM ID: 101162515 Publication Model: Print Cited Medium: Print ISSN: 1540-1405

Record details

Diagnosis and the current trends in multiple myeloma therapy.

• Authors : Dmoszyńska A; Department of Hematooncology and Bone Marrow Transplantation, Medical University, Lublin, Poland.

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Boronic Acids/Boronic Acids/Boronic Acids/*therapeutic use ; Multiple Myeloma/Multiple Myeloma/Multiple Myeloma/*diagnosis

• Source: Polskie Archiwum Medycyny Wewnetrznej [Pol Arch Med Wewn] 2008 Oct; Vol. 118 (10), pp. 563-6.Publisher: Medycyna Praktyczna Country of Publication: Poland NLM ID: 0401225 Publication Model: Print Cited Medium: Print NLM ISO Abbreviation:

Record details

[Multiple myeloma -- therapy].

• Authors : Jung W; Abteilung Hämatologie und Onkologie, Zentrum Innere Medizin, Universitätsklinikum Göttingen. ; Zettl F

Subjects: Bone Neoplasms/Bone Neoplasms/Bone Neoplasms/*drug therapy ; Boronic Acids/Boronic Acids/Boronic Acids/*therapeutic use ; Multiple Myeloma/Multiple Myeloma/Multiple Myeloma/*drug therapy

• Source: Deutsche medizinische Wochenschrift (1946) [Dtsch Med Wochenschr] 2005 Feb 11; Vol. 130 (6), pp. 283-6; quiz 287-90.Publisher: G. Thieme Country of Publication: Germany NLM ID: 0006723 Publication Model: Print Cited Medium: Print ISSN: 0012-0472 (Print)

Record details

Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.

• Authors : Landgren, O.; Iskander, K.

Subjects: MULTIPLE myeloma; HEALTH of patients; BORTEZOMIB

• Source: Journal of Internal Medicine; Apr2017, Vol. 281 Issue 4, p365-382, 18p, 2 Diagrams, 4 Charts, 2 Graphs

Record details

Pomalidomide for patients with multiple myeloma.

• Authors : Gras J; Barcelona, Spain. .

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*therapeutic use ; Multiple Myeloma/Multiple Myeloma/Multiple Myeloma/*drug therapy ; Thalidomide/Thalidomide/Thalidomide/*analogs & derivatives

• Source: Drugs of today (Barcelona, Spain : 1998) [Drugs Today (Barc)] 2013 Sep; Vol. 49 (9), pp. 555-62.Publisher: Clarivate Analytics Country of Publication: Spain NLM ID: 101160518 Publication Model: Print Cited Medium: Print ISSN: 1699-3993

Record details

Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy.

• Authors : Costacurta, Matteo; He, Jackson; Thompson, Philip E.

Subjects: SMALL molecules; MULTIPLE myeloma; DRUG design

• Source: Journal of Personalized Medicine; Nov2021, Vol. 11 Issue 11, p1185-1185, 1p

Record details

Mayo Clinic Study May Help Physicians Determine How Patients Will Respond to Multiple Myeloma Therapy.

Subjects: PROTEIN research; HUMAN abnormalities; THALIDOMIDEROCHESTER (Minn.); MINNESOTAMAYO Clinic

• Source: Biomedical Market Newsletter; 12/21/2011, Vol. 21, p1-2, 2p

Record details

Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database.

• Authors : Palmaro, Aurore; Rougé ‐ Bugat, Marie ‐ Eve; Gauthier, Martin

• Source: Pharmacoepidemiology & Drug Safety; May2017, Vol. 26 Issue 5, p578-586, 9p

Record details